116 related articles for article (PubMed ID: 23951246)
1. The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients.
Heublein S; Mayr D; Vrekoussis T; Friese K; Hofmann SS; Jeschke U; Lenhard M
PLoS One; 2013; 8(8):e71791. PubMed ID: 23951246
[TBL] [Abstract][Full Text] [Related]
2. The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function.
Meyer MR; Prossnitz ER; Barton M
Vascul Pharmacol; 2011; 55(1-3):17-25. PubMed ID: 21742056
[TBL] [Abstract][Full Text] [Related]
3. Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers.
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
Oncotarget; 2017 May; 8(20):32848-32855. PubMed ID: 28416763
[TBL] [Abstract][Full Text] [Related]
4. G protein-coupled estrogen receptor (GPER) deficiency induces cardiac remodeling through oxidative stress.
Wang H; Sun X; Lin MS; Ferrario CM; Van Remmen H; Groban L
Transl Res; 2018 Sep; 199():39-51. PubMed ID: 29758174
[TBL] [Abstract][Full Text] [Related]
5. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.
Tan TZ; Miow QH; Huang RY; Wong MK; Ye J; Lau JA; Wu MC; Bin Abdul Hadi LH; Soong R; Choolani M; Davidson B; Nesland JM; Wang LZ; Matsumura N; Mandai M; Konishi I; Goh BC; Chang JT; Thiery JP; Mori S
EMBO Mol Med; 2013 Jul; 5(7):1051-66. PubMed ID: 23666744
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen mechanically reprograms the tumor microenvironment via HIF-1A and reduces cancer cell survival.
Cortes E; Lachowski D; Robinson B; Sarper M; Teppo JS; Thorpe SD; Lieberthal TJ; Iwamoto K; Lee DA; Okada-Hatakeyama M; Varjosalo MT; Del Río Hernández AE
EMBO Rep; 2019 Jan; 20(1):. PubMed ID: 30538116
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of estrogen receptor subtypes in ovarian high-grade serous carcinoma and clear cell carcinoma.
Osaku D; Oishi T; Kawamura N; Iida Y; Komatsu H; Kudoh A; Chikumi J; Sato S; Harada T
Reprod Med Biol; 2021 Oct; 20(4):467-476. PubMed ID: 34646075
[TBL] [Abstract][Full Text] [Related]
8. Computational Approaches for the Discovery of GPER Targeting Compounds.
Grande F; Occhiuzzi MA; Lappano R; Cirillo F; Guzzi R; Garofalo A; Jacquot Y; Maggiolini M; Rizzuti B
Front Endocrinol (Lausanne); 2020; 11():517. PubMed ID: 32849301
[TBL] [Abstract][Full Text] [Related]
9. Emerging roles of GPER in diabetes and atherosclerosis.
Barton M; Prossnitz ER
Trends Endocrinol Metab; 2015 Apr; 26(4):185-92. PubMed ID: 25767029
[TBL] [Abstract][Full Text] [Related]
10. An intracellular VHH targeting the Luteinizing Hormone receptor modulates G protein-dependent signaling and steroidogenesis.
Gauthier C; Raynaud P; Jean-Alphonse F; Vallet A; Vaugrente O; Jugnarain V; Boulo T; Gauthier C; Reiter E; Bruneau G; Crépieux P
Mol Cell Endocrinol; 2024 Apr; 589():112235. PubMed ID: 38621656
[TBL] [Abstract][Full Text] [Related]
11. Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.
Blayney JK; Davison T; McCabe N; Walker S; Keating K; Delaney T; Greenan C; Williams AR; McCluggage WG; Capes-Davis A; Harkin DP; Gourley C; Kennedy RD
Nucleic Acids Res; 2016 Sep; 44(17):e137. PubMed ID: 27353327
[TBL] [Abstract][Full Text] [Related]
12. GPER Activation Inhibits Cancer Cell Mechanotransduction and Basement Membrane Invasion via RhoA.
Rice A; Cortes E; Lachowski D; Oertle P; Matellan C; Thorpe SD; Ghose R; Wang H; Lee DA; Plodinec M; Del Río Hernández AE
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991740
[TBL] [Abstract][Full Text] [Related]
13. The G-protein-coupled estrogen receptor (GPER/GPR30) in ovarian granulosa cell tumors.
Heublein S; Mayr D; Friese K; Jarrin-Franco MC; Lenhard M; Mayerhofer A; Jeschke U
Int J Mol Sci; 2014 Aug; 15(9):15161-72. PubMed ID: 25167139
[TBL] [Abstract][Full Text] [Related]
14. Synchronous profiling of mRNA N6-methyladenosine modifications and mRNA expression in high-grade serous ovarian cancer: a pilot study.
Yang L; Liu J; Jin Y; Xing J; Zhang J; Chen X; Yu A
Sci Rep; 2024 May; 14(1):10427. PubMed ID: 38714753
[TBL] [Abstract][Full Text] [Related]
15. Follicle-Stimulating Hormone Receptor Expression and Its Potential Application for Theranostics in Subtypes of Ovarian Tumors: A Systematic Review.
Bakker ME; Brink GJ; Poot AJ; Braat AJAT; Jonges GN; Zweemer RP
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539473
[TBL] [Abstract][Full Text] [Related]
16. Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancer.
Reichenbach J; Fraungruber P; Mayr D; Buschmann C; Kraus FBT; Topalov NE; Chelariu-Raicu A; Kolben T; Burges A; Mahner S; Kessler M; Jeschke U; Czogalla B; Trillsch F
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8719-8728. PubMed ID: 37131060
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical markers of prognosis in adult granulosa cell tumors of the ovary - a review.
Jung D; Almstedt K; Battista MJ; Seeger A; Jäkel J; Brenner W; Hasenburg A
J Ovarian Res; 2023 Mar; 16(1):50. PubMed ID: 36869369
[TBL] [Abstract][Full Text] [Related]
18. Selective Modulation of the Keratoconic Stromal Microenvironment by FSH and LH.
Escandon P; Nicholas SE; Vasini B; Cunningham RL; Murphy DA; Riaz KM; Karamichos D
Am J Pathol; 2023 Nov; 193(11):1762-1775. PubMed ID: 36822267
[TBL] [Abstract][Full Text] [Related]
19. Regulation of antral follicular growth by an interplay between gonadotropins and their receptors.
Casarini L; Paradiso E; Lazzaretti C; D'Alessandro S; Roy N; Mascolo E; Zaręba K; García-Gasca A; Simoni M
J Assist Reprod Genet; 2022 Apr; 39(4):893-904. PubMed ID: 35292926
[TBL] [Abstract][Full Text] [Related]
20. Molecular Characterization of Membrane Steroid Receptors in Hormone-Sensitive Cancers.
Masi M; Racchi M; Travelli C; Corsini E; Buoso E
Cells; 2021 Nov; 10(11):. PubMed ID: 34831222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
